AstraZeneca plc’s (AZN) “Hold” Rating Reaffirmed at Shore Capital

Shore Capital reaffirmed their hold rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Tuesday morning, MarketBeat Ratings reports.

A number of other brokerages have also recently issued reports on AZN. Deutsche Bank AG lowered their target price on AstraZeneca plc from GBX 5,700 ($75.22) to GBX 5,300 ($69.94) and set a buy rating for the company in a report on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($54.10) target price on AstraZeneca plc and gave the stock a sell rating in a report on Tuesday, August 8th. Sanford C. Bernstein set a GBX 5,780 ($76.27) target price on AstraZeneca plc and gave the stock a buy rating in a report on Monday, September 25th. Barclays PLC reaffirmed an overweight rating and issued a GBX 6,300 ($83.14) target price on shares of AstraZeneca plc in a report on Wednesday, July 26th. Finally, Societe Generale reaffirmed a buy rating on shares of AstraZeneca plc in a report on Monday, September 11th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the company. AstraZeneca plc has a consensus rating of Hold and a consensus price target of GBX 5,183.55 ($68.40).

Shares of AstraZeneca plc (AZN) traded up GBX 25 ($0.33) on Tuesday, reaching GBX 5,180 ($68.36). The company’s stock had a trading volume of 1,413,519 shares.

ILLEGAL ACTIVITY WARNING: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

What are top analysts saying about AstraZeneca plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca plc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit